Locher R, Suter P M, Weyhenmeyer R, Vetter W
University Hospital Zurich, Switzerland.
Arzneimittelforschung. 1998 Mar;48(3):236-9.
Low density lipoprotein (LDL) oxidation and smooth muscle cell growth represent key events in atherogenesis. Any mean to reduce these two phenomena may decrease the risk of coronary artery disease and atherosclerosis in general. The effects of silibinin (CAS 22888-70-6) on LDL oxidation and proliferation of vascular smooth muscle cells were evaluated in vitro. Silibinin (50-200 mumol/l) prolonged the lag times of both LDL autooxidation and oxidation by copper by > 50%, as assessed by recordings of diene formation. However, silibinin (up to 500 mumol/l) did not interfere with LDL-stimulated radiolabeled thymidine incorporation. These findings indicate that silibinin, apart from its hepatoprotective effects, has inhibitory properties on LDL oxidation in vitro. Therefore silibinin might represent a novel tool in the prevention and therapy of atherosclerosis.
低密度脂蛋白（LDL）氧化和平滑肌细胞生长是动脉粥样硬化形成过程中的关键事件。任何降低这两种现象的方法都可能总体上降低冠状动脉疾病和动脉粥样硬化的风险。体外评估了水飞蓟宾（CAS 22888-70-6）对LDL氧化和血管平滑肌细胞增殖的影响。通过二烯形成记录评估，水飞蓟宾（50-200 μmol/l）使LDL自氧化和铜介导氧化的延迟时间延长超过50%。然而，水飞蓟宾（高达500 μmol/l）并不干扰LDL刺激的放射性标记胸苷掺入。这些发现表明，水飞蓟宾除了具有肝脏保护作用外，在体外对LDL氧化具有抑制特性。因此，水飞蓟宾可能是预防和治疗动脉粥样硬化的一种新工具。
